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The emergence of drug resistance depends on the
ability of the genome of cancer cells to constantly
mutate and evolve under selective pressures. The
generation of new mutations is accelerated when
genes involved in DNA repair pathways are altered.
Notably, although the emergence of new mutations
fosters drug resistance, new variants can nevertheless
become novel antigens that promote immune surveillance
and even restrict cancer growth.
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surveillance1 (PD-L1) in the tumor microenvironment, which is
thought to reflect the activity of effector T cells. In a largeCancer evolution and tumor mutational burden
The ability of tumors to adapt to drug pressure depends
on the capacity of cancer cells to evolve over time. These
observations raise the important issue of how treatment
plans can overcome the near-certainty of disease relapse.
Until recently, much of the effort has been directed at
preventing or restricting tumor evolution. However, un-
derstanding the ways tumors mutate and how this af-
fects immune surveillance and immune responses could
be a more effective approach for cancer therapies.
Tumors evolve owing to their inherent genetic instabil-
ity and molecular heterogeneity. Cancers encompass dif-
ferent cellular populations carrying distinct genetic and
epigenetic alterations and are capable of continuously
acquiring new somatic variants. Several lines of evidence
indicate that tumors deficient in mismatch repair
(MMR)—characterized by hypermutability and an in-
creased mutation rate—are highly responsive to immune-
checkpoint inhibitors [1, 2]. This observation led to the
hypothesis that an increased mutation load (number of* Correspondence: alberto.bardelli@unito.it
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bimutations per megabase) could increase the efficacy of
immunotherapy. Indeed, malignancies whose etiologies
correlate with environmental exposure, such as melanoma
and lung cancers, which are characterized by a high
tumor mutational burden (TMB), have been shown to be
particularly sensitive to immunotherapy [3].
Rizvi and colleagues have reported how a higher
non-synonymous mutation burden is associated with
improved response, durable clinical benefit, and
progression-free survival in two independent cohorts of
non-small-cell lung cancer patients [1]. In their study, the
efficacy of the treatment also correlated positively with a
higher neoantigen burden. Particular attention has also
been paid to the expression of programmed death-ligand
linical data-set, it was even clearer that the expression of
D-L1 in pre-treatment biopsies identified patients most
kely to benefit from inhibitors of programmed cell death
rotein 1 (PD-1) and/or its ligand PD-L1 [4]. PD-L1 ex-
ression also strongly correlates with various markers of
ctive cellular immunity responders [5]. In patients with
oth high TMB and PD-L1 positivity, a durable response
ate of 50% was observed, suggesting that combining
hese variables can improve the ability to predict re-
ponses to checkpoint inhibitors [6]. Anti-PD-1-induced
eoantigen-specific T-cell reactivity can also be detected
the blood, and this might lead to the development of
lood-based tests to monitor responses during adminis-
ration of immune-checkpoint inhibitors [1].activation of MMR and the response to immune
heckpoint blockade
ow MMR deficiency affects the response to immuno-
herapy has been unraveled in recent work demonstrat-
g that tumors containing a high number of somatic
utations, owing to defects in DNA MMR, are sensitive
o immune-checkpoint blockade—with anti-PD-1 anti-
odies—across 12 different tumor types [2]. Objective
responses were reported in more than half of thele is distributed under the terms of the Creative Commons Attribution 4.0
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this study also demonstrated a rapid in vivo expansion
of neoantigen-specific T-cell clones reactive to tumor
mutant neopeptides. This finding strongly supports the
idea that mutant neoantigens are responsible for sensi-
tivity to immunotherapy [2].
Overall these studies underline the concept that a high
mutational burden and elevated number of neoantigens,
due to alterations in MMR genes, renders tumors respon-
sive to immunotherapy regardless of the type of cancer.
Based on these lines of evidence, the FDA granted ap-
proval to the anti-PD-1 antibody pembrolizumab in ad-
vanced solid tumors in patients whose cancer is
DNA-MMR deficient [7]. This is the first example of ap-
proval of a ‘tissue-agnostic’ treatment based on the cancer
biomarker status, rather than on tumor histology.
Although immunotherapy has shown promising results,
unfortunately it is effective in only a minority of cancer
patients, and thus there is an intense interest towards un-
derstanding why immunotherapeutic approaches might
differentially benefit distinct patient subgroups.
Immune-cold and immune-hot tumors
A major limitation of the efficacy of immunotherapy is
represented by the so-called ‘immunologically cold tu-
mors’. This term usually refers to there being limited, or
no, immune response within the tumor tissue. Cold tu-
mors are those that are not recognized by the innate or
adaptive immune system, and do not elicit strong immune
responses. Different cold immune profiles have been iden-
tified by analysis of histological samples. The ‘immune-ex-
cluded’ phenotype is characterized by the presence of
abundant immune cells that, however, do not infiltrate the
parenchyma but instead remain in the stroma of the tumor
mass [5]. A second profile, the ‘immune-desert’ phenotype,
is characterized by the absence of T cells in both the par-
enchyma and the stroma of the tumor. A third group is
represented by inflamed tumors that contain a large reper-
toire of CD8+, CD4+, and myeloid cells as well as a com-
plex network of pro-inflammatory cytokines [5]. Such
strong intra-tumoral immune abundance (that suggests a
pre-existing immune response) is blocked by the inhibitory
strategies of the tumor, preventing effective immune sur-
veillance. In addition, low levels of neoantigens, as well as
the secretion of immunosuppressive cytokines, are also
typical features of immunologically cold tumors.
Several strategies have been considered to increase im-
mune surveillance of cold tumors. For example, the im-
pact of MMR deficiency on cancer immune surveillance
was assessed recently by using syngeneic mouse models
[8]. Specifically, the gene encoding MutL homologue 1
(MLH1), a key component of the DNA MMR system,
has been genetically inactivated in colorectal, breast, and
pancreatic mouse cancer cells. While the growth ofMMR-deficient cancer cells in immunocompromised mice
was comparable to that of their proficient counterparts,
MMR-deficient cells grew poorly when transplanted into
immunocompetent mice [8]. Indeed, inactivation of MMR
not only significantly increased the mutational burden but
also led to a persistent renewal of neoantigens compared
with MMR-proficient cells. This resulted in improved im-
mune surveillance and restricted tumor growth.
Combined, these results suggest that a forced increase
in the mutational burden (particularly the levels of frame-
shifts) could, paradoxically, be beneficial. As a follow-up,
colorectal cancer mouse cell lines were treated with temo-
zolomide (TMZ), a chemotherapeutic drug that triggers
DNA damage, and TMZ-resistant cells were injected into
syngeneic mice [8]. A subset of drug-resistant cells (those
that had lost MMR capabilities) did not form tumors and
showed an increased number of mutations and number of
predicted neoantigens in comparison with parental cell
lines. Taken together, these results showed that an in-
creased mutational load, triggered by inactivation of
MMR and associated with hypermutability, can initiate an
effective immune response.
Another approach to increase the response of cancers
to immunotherapies is delivery of oncolytic viruses. For
example, a small phase Ib clinical trial recently tested
the effect of combining an oncolytic virus with the
anti-PD-1 pembrolizumab in a cohort of advanced mel-
anoma patients. This combination reported an impres-
sive 62% overall response rate, with 33% being complete
responses [9]. The strategy led to reprogramming of the
microenvironment and T-cell infiltration in tumors,
which effectively turned an immunologically cold tumor
into an immune hot tumor [9].
A further option is represented by a personalized cancer
treatment vaccine that targets patient-specific neoanti-
gens. Ott and colleagues recently showed how this ap-
proach could stimulate an effective anti-tumor response
in melanoma patients. When the vaccine was injected into
the patients, it drove immune T-cell responses that recog-
nized neoantigens on tumor cells, resulting in complete
responses [10]. Oncogenic driver mutations are required
for the tumor growth, but they can also be considered as
tumor-specific neoantigens, shared among patients. Ro-
senberg and colleagues evaluated the reactivity of
tumor-infiltrating CD8+ T lymphocytes that specifically
recognized KRAS harboring the G12D mutation in a pa-
tient with multiple metastatic sites. After the lymphocytes
were expanded and infused, an objective regression was
observed for all seven lung metastases [11].
Other strategies to convert an immune-cold tumor
into an immune-hot target include the use of nanoparti-
cles capable of delivering immune-stimulating drugs into
tumors and, in turn, stimulating T-cell invasion. Repro-
gramming the tumor microenvironment to elicit T-cell
Truini et al. Genome Medicine           (2018) 10:91 Page 3 of 3activation and enhance tumor immunity represents an-
other way to effectively convert cold tumors into hot tu-
mors. Finally, small-molecule drugs that increase T-cell
activity could act synergistically with immune-checkpoint
inhibitors.
Concluding remarks
Up until now, significant efforts have been made in the
direction of preventing and/or restricting tumor evolution
for therapeutic strategies. An alternative approach is to in-
crease the immunogenicity of cancer cells, thus fostering
immune surveillance. In this regard, several strategies have
been proposed, including, first, inactivation of DNA repair
to increase neoantigen levels in cancer cells; second,
modification of the tumor microenvironment; and finally
delivering tumor-specific viruses. These approaches are
being tested in preclinical models or in early-stage clinical
experimentation, with the ultimate goal of improving im-
mune surveillance and restricting cancer growth.
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